VONVENDI Rx

Select the drug indication to add to your list

VONVENDI

Bleeding disorders
Only 4 drugs may be compared at once

Generic Name and Formulations:

Von Willebrand Factor (recombinant); 650 IU VWF:RCo, 1300 IU VWF:RCo; per vial; lyophilized pwd for IV inj after reconstitution; preservative-free.

Company:

Baxalta

Select therapeutic use:

Indications for VONVENDI:

On-demand treatment and control of bleeding episodes in adults with von Willebrand disease (VWD).

Adult:

Give recombinant factor VIII (FVIII) with first infusion if baseline plasma FVIII level <40% or is unknown (see full labeling). ≥18yrs: Minor bleed: initially 40–50 IU/kg, then every 8–24 hours as needed. Major bleed: initially 50–80 IU/kg, then 40–60 IU/kg every 8–24 hours for 2–3 days as needed. Monitor and adjust according to extent and location of bleed. Max infusion rate: 4mL/min.

Children:

<18yrs: not established.

Contraindications:

Hypersensitivity to hamster or mouse proteins.

Warnings/Precautions:

Treatment should be supervised by physician. Risk of thrombotic events in patients with known risk factors or an excessive rise in FVIII levels; monitor. Discontinue immediately if severe allergic reactions occur. Ineffectiveness may indicate antibody formation; monitor and consider alternative therapy. Pregnancy. Nursing mothers.

Pharmacological Class:

Clotting factor.

Adverse Reactions:

Generalized pruritus; antibody formation.

Generic Availability:

NO

How Supplied:

Single-use vials—1 (w. diluent, supplies)